Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Phase II EMN19 study of Dara-VCd in EMD patients shows overall heme ≥CR rate 47.5% (19/40; NDMM: 58.6%; RRMM: 18.2%); in CRs, MRD negativity 68.4% (13/19); median PFS 25.8 months, significantly longer in patients achieving heme ≥CR.”
Title: Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study
Authors: Meral Beksac, Tulin Fıratlı Tuglular, Francesca Gay, Roberto Mina, Eirini Katodritou, Ali Unal, Michele Cavo, Guner Hayri Ozsan, Vincent H. J. van der Velden, Berna H. Beverloo, Michael Vermeulen, Mark van Duin, Guldane Cengiz Seval, Omur Gokmen Sevindik, Serena Merante, Kyriaki Manousou, Peter Sonneveld, Elena Zamagni, Evangelos Terpos
You can read the Full Article in HemaSphere.
You can find more posts featuring Robert Orlowski on OncoDaily.
